The test measures plasma amyloid beta and phosphorylated tau 217 to determine the likelihood that a person has the brain amyloid pathology characteristic of Alzheimer's disease.

Beckman Coulter will use the platform to unify data across its instruments and systems to provide standardized performance metrics and AI-based analytics.

Last week, readers were most interested in a story about Dxcover's platform, which integrates infrared spectroscopy with proprietary algorithms, receiving Class C certification.

The system consists of a microfluidic cartridge with 640 incubation wells that allows the platform to visually test all clinically relevant antibiotics quantitatively.

The firm expects to reach patients who might otherwise avoid medical appointments by offering screening tests through dentists.

The Irvine, California-based company will now market its test to clinical labs throughout the UK for patient testing.